Caffeine Interactions

CYP1A2 inhibitor that increases warfarin effect and INR; requires close INR monitoring

Source: NLP:warfarin

CYP1A2 inhibitor that increases warfarin effect and INR; requires close INR monitoring.

Source: NLP:warfarin sodium

Antagonizes the effects of adenosine, potentially reducing efficacy. Larger doses of adenosine may be required.

Source: NLP:adenosine

Systemic quinolones including ciprofloxacin interfere with the metabolism of caffeine.

Source: NLP:ciprofloxacin

Systemic quinolones including ciprofloxacin interfere with the metabolism of caffeine.

Source: NLP:ciprofloxacin hydrochloride

Moderate or weak CYP1A2 inhibitor that may increase clozapine levels. Monitor patients closely and consider dose reduction if necessary.

Source: NLP:clozapine

Deferasirox inhibits CYP1A2 resulting in increased caffeine concentration. Monitor for exposure related toxicity.

Source: NLP:deferasirox

Smoking cessation with nicotine replacement may require dose decrease due to deinduction of hepatic enzymes.

Source: NLP:nicotine

Systemic administration of quinolones interferes with the metabolism of caffeine.

Source: NLP:ofloxacin

Methylxanthine that interferes with the vasodilation activity of regadenoson. Patients should avoid consumption for at least 12 hours before regadenoson administration.

Source: NLP:regadenoson

Stiripentol is an inhibitor and inducer of CYP1A2; consider dose adjustment of caffeine when administered concomitantly with DIACOMIT.

Source: NLP:stiripentol

Terbinafine decreases caffeine clearance by 19%, potentially increasing caffeine exposure.

Source: NLP:terbinafine hydrochloride

Terbinafine decreases the clearance of caffeine by 19%.

Source: NLP:terbinafine tablets 250 mg

Terbinafine decreases caffeine clearance by 19%.

Source: NLP:terbinafine